Jane Street Group, LLC Prelude Therapeutics Inc Transaction History

Jane Street Group, LLC

  • $445 Billion
  • Q3 2024

A detailed history of Jane Street Group, LLC transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Jane Street Group, LLC holds 10,361 shares of PRLD stock, worth $9,946. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,361
Previous 12,948 19.98%
Holding current value
$9,946
Previous $49,000 57.14%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$2.07 - $6.37 $5,355 - $16,479
-2,587 Reduced 19.98%
10,361 $21,000
Q2 2024

Aug 14, 2024
SELL
$3.32 - $5.63 $11,420 - $19,367
-3,440 Reduced 20.99%
12,948 $49,000
Q1 2024

May 15, 2024
SELL
$2.68 - $4.84 $44,458 - $80,290
-16,589 Reduced 50.3%
16,388 $77,000
Q4 2023

Feb 14, 2024
BUY
$1.69 - $4.37 $55,731 - $144,109
32,977 New
32,977 $140,000
Q1 2023

May 15, 2023
BUY
$4.58 - $7.34 $218,296 - $349,846
47,663 Added 283.59%
64,470 $367,000
Q4 2022

Feb 14, 2023
BUY
$4.61 - $8.5 $77,480 - $142,859
16,807 New
16,807 $101,000
Q1 2022

May 17, 2022
SELL
$6.9 - $13.22 $70,662 - $135,386
-10,241 Closed
0 $0
Q4 2021

Feb 15, 2022
BUY
$11.89 - $31.74 $121,765 - $325,049
10,241 New
10,241 $128,000
Q4 2020

Feb 17, 2021
SELL
$28.81 - $88.94 $212,473 - $655,932
-7,375 Closed
0 $0
Q3 2020

Nov 17, 2020
BUY
$26.2 - $30.13 $193,225 - $222,208
7,375 New
7,375 $222,000

Others Institutions Holding PRLD

# of Institutions
71
Shares Held
35.7M
Call Options Held
500
Put Options Held
300
View Full List

About Prelude Therapeutics Inc

PRLD Quotes by TradingView
  • Ticker PRLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,369,200
  • Market Cap $34.9M
  • Description
  • Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...
More about PRLD
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email